Growing Global Vaccine Market Helping Spur Drug Companies To Pursue Ebola Vaccine

The New Yorker: The Race for an Ebola Vaccine
“…So why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson — three of the world’s biggest drug manufacturers? … [O]ver the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription drug market…” (Vara, 11/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.